Executive Summary
The majority of the council believes Nike remains a high-quality global franchise but faces meaningful cyclical and structural headwinds that warrant patience rather than immediate accumulation. Revenue has declined from $51.4B in 2023 to $46.3B in 2024, with net income dropping from $5.7B to $3.2B and ROIC falling from 25% to 10.9%. These figures indicate temporary dislocation but not permanent impairment of the brand moat. Buffett, Munger, Vinall, and Prasad argue that the brand’s global reach, pricing power, and marketing scale still constitute a durable competitive advantage, even though recent execution has faltered. They note that Nike’s historical ability to restore margins and ROIC through product innovation and disciplined cost control supports a 'Buy Lower' stance. The group sees fair value around $80 based on a normalized mid-cycle EPS of $3.00 (average of 2020–2023 excluding the COVID trough) and a conservative 26x multiple, consistent with premium consumer brand valuation. However, they caution that margin recovery will take time, and that investors should demand a margin of safety given negative book equity and China weakness. The consensus view is to wait for a more attractive entry point near $60–$65, where risk/reward becomes compelling. The majority expects gradual improvement over 12–24 months as inventory normalization, digital restructuring, and tariff mitigation unfold.
The minority believes Nike’s deterioration is not merely cyclical but indicative of structural erosion in its moat and management discipline. Dev Kantesaria, Mohnish Pabrai, and David Tepper argue that the collapse in ROIC, margin compression, and negative book equity signify a business losing its fundamental compounding characteristics. The shift from high-margin direct-to-consumer to wholesale growth and the 16% China revenue decline highlight strategic missteps that may persist. They view the normalized EPS assumption of $3.00 as unrealistic given trailing EPS of $1.96 and operating margins at 7.36%. The minority therefore recommends 'Avoid Stock' until clear evidence of margin stabilization and ROIC recovery above 15% emerges. They see no inevitability of success over the next decade, which violates Dev Kantesaria’s long-duration compounding criteria.